Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 12:16:1560834.
doi: 10.3389/fphar.2025.1560834. eCollection 2025.

Prodrug-carboxypeptidase G2 therapy: certain concerns on carboxypeptidase G2

Tinghe Yu  1 , Tianran Yu  2 , Xinya Li  1
Affiliations

Prodrug-carboxypeptidase G2 therapy: certain concerns on carboxypeptidase G2

Tinghe Yu et al. Front Pharmacol. .
No abstract available

Keywords: antidrug antibody; enzyme kinetics; pharmacokinetics; prodrug-carboxypeptidase G2 therapy; therapeutic time window.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

FIGURE 1
FIGURE 1
Blood drug level vs. time curves of ZD2767P and CPG2: PK property of CPG2 did not match with that of ZD2767P (data were from Napier et al., 2000; Francis et al., 2002; Mayer et al., 2006; Yu and Li, 2023).
See this image and copyright information in PMC

References

    1. Al-mansoori L., Bashraheel S. S., Al Qahtani A. D., O'Connor C. D., Elsinga P., Goda S. K. (2020). In vitro studies on CNGRC-CPG2 fusion proteins for ligand directed enzyme prodrug therapy for targeted cancer therapy. Oncotarget 11, 619– 633. 10.18632/oncotarget.27478 - DOI - PMC - PubMed
    1. Al-mansoori L., Al Qahtani A. D., Elsinga P., Goda S. K. (2021). Production of long-acting CNGRC-CPG2 fusion proteins: new derivatives to overcome drug immunogenicity of ligand-directed enzyme prodrug therapy for targeted cancer treatment. Technol. Cancer Res. Treat. 20, 15330338211057371. 10.1177/15330338211057371 - DOI - PMC - PubMed
    1. AlQahtani A. D., Al-mansoori L., Bashraheel S. S., Rashidi F. B., Al-Yafei A., Elsinga P., et al. (2019). Production of “biobetter” glucarpidase variants to improve drug detoxification and antibody directed enzyme prodrug therapy for cancer treatment. Eur. J. Pharm. Sci. 127, 79–91. 10.1016/j.ejps.2018.10.014 - DOI - PubMed
    1. Al-Qahtani A. D., Bashraheel S. S., Rashidi F. B., O'Connor C. D., Romero A. R., Domling A., et al. (2019). Production of “biobetter” variants of glucarpidase with enhanced enzyme activity. Biomed. Pharmacother. 112, 108725. 10.1016/j.biopha.2019.108725 - DOI - PubMed
    1. Bielack S. S., Soussain C., Fox C. P., Houillier C., Murciano T., Osborne W., et al. (2024). A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. J. Cancer Res. Clin. Oncol. 150, 441. 10.1007/s00432-024-05945-6 - DOI - PMC - PubMed

LinkOut - more resources